Biotherapic 200dH is harmful to acute murine infection with Trypanosoma cruzi.
AbstractBiotherapics employed to treat mice infected by Trypanosoma cruzi were carried out with encouraging results. The aim of this study was evaluated the effect of biotherapic of Trypanosoma cruzi 200dH, using two different schedules of treatment. Swiss male mice, aged 56 days-old were infected intraperitonealy with 1,400 blood trypomastigotes of Trypanosoma cruzi Y strain and were divided into groups: C.I.- infected animals, E.D. – Infected animals treated from the day 1 until the end of the experiment; 200dH S.D. – Infected animals treated on the day 1. Parasitological, clinical and immunological parameters were evaluated. The group of animals that received the medicine in a single dose presented higher value to total parasitaemia and lower value of pre patent period compared to control untreated group (p<0.05), as well as the number of amastigotes which was also higher for this group (S.D.) (p<0.05). Clinically, the S.D.group presented more stable temperature (p<0.05) but not presented another clinical difference among treatments. IL-6 and TNF-α presented similar dosage among treated groups as well as IL-4 and IL-10. IL-17A and INF-γ, presented highest values to S.D. group (p<0.05). All animals died until the 20th day of infection.
The lack of improvement in clinical and parasitological parameters, the untimely death and the immunological imbalance display the harmful evolution of the experimental infection by T. cruzi using biotherapic 200dH. The results could be useful for homeopathic physicians. In human clinical use, the choice of dynamizations and treatment schedule should consider acute and chronic diseases to achieve the expected results.
Upon acceptance of an article for publication, author(s) recognize Groupe International de Recherche sur l'InfinitÃƒÂ©simale (GIRI) as the Licensor. International Journal of High Dilution Research (IJHDR) has adopted Creative Commons Public License (CCPL) as CC-by-nc-nd.Licensed to GIRI under CCPL.
Under this license, others are allowed to download your article from IJHDR website and share it with others as long as they mention authors and licensor as well as link back to IJHDR, but they cannot change it any way nor can use it for commercial purposes.
More information at: http://creativecommons.org/licenses/by-nc-nd/3.0/legalcode